Autodesk Inc vs BridgeBio Pharma Inc — how do they compare? Autodesk Inc trades at $250.6 (market cap $54.07B), while BridgeBio Pharma Inc trades at $83.9 (market cap $16.61B). The key difference: Autodesk Inc is far larger — about 3.3× BridgeBio Pharma Inc's market cap, and BridgeBio Pharma Inc is trading nearer its 52-week high, Autodesk Inc nearer its low. Which is the better fit depends on your goals.
| ADSK | BBIO | |
|---|---|---|
Market Cap | $54.07B | $16.61B |
Sector | Technology | Health |
52-Week High | $326.79 | $90.17 |
52-Week Low | $187.72 | $47.29 |
Enterprise Value | $53.87B | $18.16B |
Signals from Pluang's Aura AI — not financial advice
Autodesk (ADSK) trades at $249.08, up 2.73% on the day, with a bullish technical signal and strong fundamental performance. Revenue grew to $6.13B in 2025, with net income reaching $1.11B and a 19.49% net margin. The stock has consistently beaten earnings estimates, with Q1 2026 EPS of $2.99 exceeding the $2.84 forecast. Analyst consensus is a Buy with a $305.31 price target, supported by 74.51% of analysts rating it a Buy. Recent news highlights AI investments and strategic acquisitions.
Outlook remains positive given robust earnings growth, high profitability margins, and strategic AI investments. Risks include competitive pressures in software, reliance on economic cycles affecting design software demand, and execution risks from recent acquisitions. The stock offers upside to the consensus target but faces volatility near technical resistance at $253.
BridgeBio Pharma (BBIO) trades at $84.48, up 2.03% with bullish technical signals from moving averages. Despite strong revenue growth from $222M in 2024 to $502M in 2025, the company reports significant losses with a -144.39% net margin. Recent FDA acceptance for encaleret in ADH1 and Attruby's commercial expansion in ATTR-CM provide growth catalysts, though cash flow remains negative at -$111M in 2025.
The stock presents high-risk growth potential with 88% analyst buy ratings and $102.20 consensus target, but faces substantial execution risks from ongoing losses and $1.72B debt load. Success hinges on pipeline approvals and Attruby's market penetration, making it suitable for risk-tolerant investors betting on biotech breakthroughs.
Trailing returns across standard periods
Latest headlines on both assets
Founded in 1982, Autodesk is an application software company that serves industries in architecture, engineering, and construction.
Read more on ADSK →BridgeBio Pharma Inc is involved in identifying advance transformative medicines to treat patients who suffer from Mendelian diseases, which are diseases that arise from defects in a single gene, and cancers with clear genetic drivers. Its product pipeline categories include Mendelian, Genetic Dermatology, Oncology, and Gene therapy.
Read more on BBIO →